Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices

Pre-clinical and clinical experience

Jorge E. Romero, Andrea Natale, Krysthel Engstrom, Luigi Di Biase

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in the elderly population and it is associated with a four-fold to five-fold increased risk of thromboembolic events. It was not until the mid-1950s that the left atrial appendage (LAA) was identified as the main location of thrombus formation, particularly in patients with non-valvular AF. In this review, we explain at some extent its embryology, anatomy and physiology, and as well as the clinical and pre-clinical trials published to date testing the safety and efficacy of most LAA closure devices. Among those devices, the most studied include the PLAATO system (ev3 Endovascular, Plymouth, MN), the Amplatzer cardiac plug (St Jude, Golden Valley, MN; St. Jude Medical, Minneapolis, MN), the WATCHMAN device (Boston Scientific, Plymouth, MN; Atritech Inc., Plymouth, MN), and the LARIAT device (SentreHEART, Palo Alto, CA). Similarly, newer LAA closure devices currently under investigation such as the Transcatheter Patch (Custom Medical Devices, Athens, Greece), AEGIS, and the Coherex WaveCrest (Salt Lake City, UT) will also be discussed. Future perspectives and the need for well-designed prospective studies between devices and new oral anticoagulant drugs are also proposed.

Original languageEnglish (US)
Pages (from-to)182-199
Number of pages18
JournalTrends in Cardiovascular Medicine
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Atrial Appendage
Equipment and Supplies
Atrial Fibrillation
Embryology
Greece
Anticoagulants
Cardiac Arrhythmias
Anatomy
Thrombosis
Clinical Trials
Prospective Studies
Safety
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices : Pre-clinical and clinical experience. / Romero, Jorge E.; Natale, Andrea; Engstrom, Krysthel; Di Biase, Luigi.

In: Trends in Cardiovascular Medicine, Vol. 26, No. 2, 01.02.2016, p. 182-199.

Research output: Contribution to journalArticle

@article{755ff8e387a347b5b9927d12156f5385,
title = "Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices: Pre-clinical and clinical experience",
abstract = "Atrial fibrillation (AF) is the most common arrhythmia in the elderly population and it is associated with a four-fold to five-fold increased risk of thromboembolic events. It was not until the mid-1950s that the left atrial appendage (LAA) was identified as the main location of thrombus formation, particularly in patients with non-valvular AF. In this review, we explain at some extent its embryology, anatomy and physiology, and as well as the clinical and pre-clinical trials published to date testing the safety and efficacy of most LAA closure devices. Among those devices, the most studied include the PLAATO system (ev3 Endovascular, Plymouth, MN), the Amplatzer cardiac plug (St Jude, Golden Valley, MN; St. Jude Medical, Minneapolis, MN), the WATCHMAN device (Boston Scientific, Plymouth, MN; Atritech Inc., Plymouth, MN), and the LARIAT device (SentreHEART, Palo Alto, CA). Similarly, newer LAA closure devices currently under investigation such as the Transcatheter Patch (Custom Medical Devices, Athens, Greece), AEGIS, and the Coherex WaveCrest (Salt Lake City, UT) will also be discussed. Future perspectives and the need for well-designed prospective studies between devices and new oral anticoagulant drugs are also proposed.",
author = "Romero, {Jorge E.} and Andrea Natale and Krysthel Engstrom and {Di Biase}, Luigi",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.tcm.2015.05.009",
language = "English (US)",
volume = "26",
pages = "182--199",
journal = "Trends in Cardiovascular Medicine",
issn = "1050-1738",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Left atrial appendage isolation using percutaneous (endocardial/epicardial) devices

T2 - Pre-clinical and clinical experience

AU - Romero, Jorge E.

AU - Natale, Andrea

AU - Engstrom, Krysthel

AU - Di Biase, Luigi

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Atrial fibrillation (AF) is the most common arrhythmia in the elderly population and it is associated with a four-fold to five-fold increased risk of thromboembolic events. It was not until the mid-1950s that the left atrial appendage (LAA) was identified as the main location of thrombus formation, particularly in patients with non-valvular AF. In this review, we explain at some extent its embryology, anatomy and physiology, and as well as the clinical and pre-clinical trials published to date testing the safety and efficacy of most LAA closure devices. Among those devices, the most studied include the PLAATO system (ev3 Endovascular, Plymouth, MN), the Amplatzer cardiac plug (St Jude, Golden Valley, MN; St. Jude Medical, Minneapolis, MN), the WATCHMAN device (Boston Scientific, Plymouth, MN; Atritech Inc., Plymouth, MN), and the LARIAT device (SentreHEART, Palo Alto, CA). Similarly, newer LAA closure devices currently under investigation such as the Transcatheter Patch (Custom Medical Devices, Athens, Greece), AEGIS, and the Coherex WaveCrest (Salt Lake City, UT) will also be discussed. Future perspectives and the need for well-designed prospective studies between devices and new oral anticoagulant drugs are also proposed.

AB - Atrial fibrillation (AF) is the most common arrhythmia in the elderly population and it is associated with a four-fold to five-fold increased risk of thromboembolic events. It was not until the mid-1950s that the left atrial appendage (LAA) was identified as the main location of thrombus formation, particularly in patients with non-valvular AF. In this review, we explain at some extent its embryology, anatomy and physiology, and as well as the clinical and pre-clinical trials published to date testing the safety and efficacy of most LAA closure devices. Among those devices, the most studied include the PLAATO system (ev3 Endovascular, Plymouth, MN), the Amplatzer cardiac plug (St Jude, Golden Valley, MN; St. Jude Medical, Minneapolis, MN), the WATCHMAN device (Boston Scientific, Plymouth, MN; Atritech Inc., Plymouth, MN), and the LARIAT device (SentreHEART, Palo Alto, CA). Similarly, newer LAA closure devices currently under investigation such as the Transcatheter Patch (Custom Medical Devices, Athens, Greece), AEGIS, and the Coherex WaveCrest (Salt Lake City, UT) will also be discussed. Future perspectives and the need for well-designed prospective studies between devices and new oral anticoagulant drugs are also proposed.

UR - http://www.scopus.com/inward/record.url?scp=84959081526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959081526&partnerID=8YFLogxK

U2 - 10.1016/j.tcm.2015.05.009

DO - 10.1016/j.tcm.2015.05.009

M3 - Article

VL - 26

SP - 182

EP - 199

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

SN - 1050-1738

IS - 2

ER -